135 related articles for article (PubMed ID: 35276469)
1. Refractory Hyperammonemic encephalopathy in Fibrolamellar hepatocellular carcinoma, a case report and literature review.
Ahmed A; Ata F; Gaber M; Petkar M; Mahfouz A; Schirmacher P; Musa S; Hashim A
Curr Probl Cancer; 2022 Jun; 46(3):100847. PubMed ID: 35276469
[TBL] [Abstract][Full Text] [Related]
2. Hyperammonemic Encephalopathy Mimicking Ornithine Transcarbamylase Deficiency in Fibrolamellar Hepatocellular Carcinoma: Successful Treatment with Continuous Venovenous Hemofiltration and Ammonia Scavengers.
Lee JS; Jin HY; Ko JM; Kim SH; Han N; Park BK; Park M; Park HJ; Lee JA
Cancer Res Treat; 2021 Jan; 53(1):283-288. PubMed ID: 32898940
[TBL] [Abstract][Full Text] [Related]
3. Hyperammonemic encephalopathy in a patient with fibrolamellar hepatocellular carcinoma: case report and literature review.
Cho J; Chen JCY; Paludo J; Conboy EE; Lanpher BC; Alberts SR; Halfdanarson TR
J Gastrointest Oncol; 2019 Jun; 10(3):582-588. PubMed ID: 31183212
[TBL] [Abstract][Full Text] [Related]
4. Hyperammonemic Encephalopathy Associated With Fibrolamellar Hepatocellular Carcinoma: Case Report, Literature Review, and Proposed Treatment Algorithm.
Chapuy CI; Sahai I; Sharma R; Zhu AX; Kozyreva ON
Oncologist; 2016 Apr; 21(4):514-20. PubMed ID: 26975868
[TBL] [Abstract][Full Text] [Related]
5. A Proposed Physiopathological Pathway to Hyperammonemic Encephalopathy in a Non-Cirrhotic Patient with Fibrolamellar Hepatocellular Carcinoma without Ornithine Transcarbamylase (OTC) Mutation.
Surjan RC; Dos Santos ES; Basseres T; Makdissi FF; Machado MA
Am J Case Rep; 2017 Mar; 18():234-241. PubMed ID: 28270654
[TBL] [Abstract][Full Text] [Related]
6. Pharmacotherapies that specifically target ammonia for the prevention and treatment of hepatic encephalopathy in adults with cirrhosis.
Zacharias HD; Zacharias AP; Gluud LL; Morgan MY
Cochrane Database Syst Rev; 2019 Jun; 6(6):CD012334. PubMed ID: 31204790
[TBL] [Abstract][Full Text] [Related]
7. Hyperammonemic Encephalopathy Exacerbated by Parenteral Nutrition in Fibrolamellar Hepatocellular Carcinoma.
Shah PA; Cho J; Albitar HAH; Pajot G; Liu M; Ravi K
Am J Med; 2020 Dec; 133(12):e745-e746. PubMed ID: 32739410
[No Abstract] [Full Text] [Related]
8. Acquired ornithine transcarbamylase deficiency in pediatric and adolescent patients with fibrolamellar hepatocellular carcinoma.
Bartlett AL; Leslie ND; Gupta A; Geller JI
Pediatr Blood Cancer; 2018 Dec; 65(12):e27392. PubMed ID: 30094907
[TBL] [Abstract][Full Text] [Related]
9. Postchemotherapy hyperammonemic encephalopathy emulating ornithine transcarbamoylase (OTC) deficiency.
Chan JS; Harding CO; Blanke CD
South Med J; 2008 May; 101(5):543-5. PubMed ID: 18414167
[TBL] [Abstract][Full Text] [Related]
10. An 18-year-old woman with a 15-cm liver mass and an ammonia level of 342.
Hashash JG; Thudi K; Malik SM
Gastroenterology; 2012 Nov; 143(5):1157-1402. PubMed ID: 23000233
[No Abstract] [Full Text] [Related]
11. Hyperammonemic encephalopathy: a rare presentation of fibrolamellar hepatocellular carcinoma.
Sethi S; Tageja N; Singh J; Arabi H; Dave M; Badheka A; Revankar S
Am J Med Sci; 2009 Dec; 338(6):522-4. PubMed ID: 20010160
[TBL] [Abstract][Full Text] [Related]
12. Hyperammonemia in a patient with late-onset ornithine carbamoyltransferase deficiency.
Choi DE; Lee KW; Shin YT; Na KR
J Korean Med Sci; 2012 May; 27(5):556-9. PubMed ID: 22563224
[TBL] [Abstract][Full Text] [Related]
13. Fibrolamellar hepatocellular carcinoma presenting as cholestatic jaundice: An unusual presentation of a rare disease.
Singh A; Goyal S; Mehta V; Kakkar C; Narang V; Sood A
Indian J Pathol Microbiol; 2023; 66(2):385-387. PubMed ID: 37077092
[TBL] [Abstract][Full Text] [Related]
14. Female heterozygotes for the hypomorphic R40H mutation can have ornithine transcarbamylase deficiency and present in early adolescence: a case report and review of the literature.
Pinner JR; Freckmann ML; Kirk EP; Yoshino M
J Med Case Rep; 2010 Nov; 4():361. PubMed ID: 21070677
[TBL] [Abstract][Full Text] [Related]
15. Surgical Debulking for Refractory Hyperammonemic Encephalopathy in Fibrolamellar Hepatocellular Carcinoma.
Solipuram V; Baretti M; Kim AY; Chen LX; Fahrner JA; Gunay-Aygun M; Peng XP; Hardenbergh D; Ferguson A; Griffith P; Wang Y; Brancati M; Gopalakrishna H; Kato T; Shubert C; Laheru D; Yarchoan M
Hepatology; 2021 Nov; 74(5):2899-2901. PubMed ID: 34105830
[No Abstract] [Full Text] [Related]
16. [Hyperammonemic encephalopathy and fibrolamellar hepatocellular carcinoma].
Berger C; Dimant P; Hermida L; Paulin F; Pereyra M; Tejo M
Medicina (B Aires); 2012; 72(5):425-7. PubMed ID: 23089120
[TBL] [Abstract][Full Text] [Related]
17. Predictors of nonresponse to lactulose in patients with cirrhosis and hepatic encephalopathy.
Sharma P; Sharma BC; Sarin SK
Eur J Gastroenterol Hepatol; 2010 May; 22(5):526-31. PubMed ID: 20009938
[TBL] [Abstract][Full Text] [Related]
18. Fibrolamellar hepatocellular carcinoma in a Japanese man: report of a case.
Yoshimi F; Asato Y; Amemiya R; Itabashi M; Nakamura K
Surg Today; 2002; 32(2):174-9. PubMed ID: 11998950
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Rifaximin Plus Lactulose with the Lactulose Alone for the Treatment of Hepatic Encephalopathy.
Ahire K; Sonawale A
J Assoc Physicians India; 2017 Aug; 65(8):42-46. PubMed ID: 28799305
[TBL] [Abstract][Full Text] [Related]
20. Current trends in the treatment of hepatic encephalopathy.
Al Sibae MR; McGuire BM
Ther Clin Risk Manag; 2009 Jun; 5(3):617-26. PubMed ID: 19707277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
